Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 3, 2011, Pages 767-777

  Lakatos, Peter Laszlo ^a   Kiss, Lajos Sandor ^a   Palatka, Karoly ^b   Altorjay, Istvan ^b   Antal Szalmas, Peter ^b   Palyu, Eszter ^b   Udvardy, Miklos ^b   Molnar, Tamas ^c   Farkas, Klaudia ^c   Veres, Gabor ^a   Harsfalvi, Jolan ^b   Papp, Janos ^a   Papp, Maria ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

CD; disease activity; flare up; LBP; phenotype; sCD14

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; IMMUNOGLOBULIN A; LIPOPOLYSACCHARIDE BINDING PROTEIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACUTE-PHASE PROTEINS; ADULT; ANTIGENS, CD14; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARRIER PROTEINS; CASE-CONTROL STUDIES; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NOD2 SIGNALING ADAPTOR PROTEIN; PHENOTYPE; POLYMORPHISM, GENETIC; PROGNOSIS; SURVIVAL RATE;

EID: 79951603051     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21402     Document Type: Article

References (40)

1. Lakatos PL,. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006; 12: 6102-6108. (Pubitemid 44688157)
2. Vermeire S, VanAssche G, Rutgeerts P,. Laboratory markers in IBD: useful magic or unnecessary toys? Gut. 2006; 55: 426-431. (Pubitemid 43268284)
3. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010; 105: 162-169.
4. Brignola C, Campieri M, Bazzocchi G, et al. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology. 1986; 91: 1490-1494. (Pubitemid 17176866)
5. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C-reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988; 10: 401-405.
6. Consigny Y, Modigliani R, Colombel JF, et al (GETAID). A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis. 2006; 12: 551-557. (Pubitemid 43977735)
7. Henriksen M, Jahnsen J, Lygren I, et al, IBSEN Study Group. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008; 57: 1518-1523.
8. Schuetz P, Christ-Crain M, Müller B,. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care. 2007; 13: 578-585. (Pubitemid 47357461)
9. Yu B, Hailman E, Wright SD,. Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest. 1997; 99: 315-324. (Pubitemid 27053990)
10. Zweigner J, Schumann RR, Weber JR,. The role of lipopolysaccharide- binding protein in modulating the innate immune response. Microbes Infect. 2006; 8: 946-952.
11. Kitchens RL, Thompson PA,. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res. 2005; 11: 225-229. (Pubitemid 41358857)
12. Geller DA, Kispert PH, Su GL, et al. Induction of hepatocyte lipopolysaccharide binding protein in models of sepsis and the acute-phase response. Arch Surg. 1993; 128: 22-27.
13. Froon AH, Dentener MA, Greve JW, et al. Lipopolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis. 1995; 171: 1250-1257.
14. Pavcnik-Arnol M, Hojker S, Derganc M,. Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein. Intensive Care Med. 2004; 30: 1454-1460. (Pubitemid 38951731)
15. Gazouli M, Mantzaris G, Kotsinas A, et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol. 2005; 11: 681-685. (Pubitemid 40220757)
16. Klein W, Tromm A, Griga T, et al. A polymorphism in the CD14 gene is associated with Crohn disease. Scand J Gastroenterol. 2002; 37: 189-191. (Pubitemid 34102256)
17. Petermann I, Huebner C, Browning BL, et al. Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Hum Immunol. 2009; 70: 440-446.
18. Klausz G, Molnár T, Nagy F, et al. Polymorphism of the heat-shock protein gene Hsp70-2, but not polymorphisms of the IL-10 and CD14 genes, is associated with the outcome of Crohn's disease. Scand J Gastroenterol. 2005; 40: 1197-1204. (Pubitemid 41510679)
19. Papp M, Altorjay I, Norman GL, et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inlfamm Bowel Dis. 2007; 13: 984-992. (Pubitemid 47309970)
20. de Buhr MF, Hedrich HJ, Westendorf AM, et al. Analysis of Cd14 as a genetic modifier of experimental inflammatory bowel disease (IBD) in mice. Inflamm Bowel Dis. 2009; 15: 1824-1836.
21. Pastor Rojo O, Lõpez San Román A, Albéniz Arbizu E, et al. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 269-277.
22. Pasternak BA, D'Mello S, Jurickova II, et al. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis. 2010; 16: 856-869.
23. Zilberman L, Maharshak N, Arbel Y, et al. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Digestion. 2006; 73: 205-209. (Pubitemid 44448880)
24. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989; 24 (suppl 170): 2-6. (Pubitemid 20015811)
25. Stange EF, Travis SPL, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55 (suppl i): i1-i15. (Pubitemid 43268290)
26. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439-444.
27. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (suppl A): 5-36.
28. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003; 37: 208-217. (Pubitemid 36042162)
29. Albillos A, de-la-Hera A, Alvarez-Mon M,. Serum lipopolysaccharide- binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet. 2004; 363: 1608-1610. (Pubitemid 38625665)
30. Tibble JA, Bjarnason I,. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001; 7: 460-465. (Pubitemid 32782620)
31. Lakatos PL, Fischer S, Lakatos L, et al. Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take "toll"? World J Gastroenterol. 2006; 12: 1829-1840.
32. Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut. 2006; 55: 342-347. (Pubitemid 43268271)
33. Papp M, Foldi I, Altorjay I, et al. Anti-microbial antibodies in celiac disease: trick or treat? World J Gastroenterol. 2009; 15: 3891-3900.
34. Papp M, Vitalis Z, Tornai I, et al. Presence of anti-microbial antibodies is associated with increased risk for systemic infections in a large Hungarian cohort of patients with liver cirrhosis. Gut. 2009; 58 () suppl II A358: 1254.
35. Papp M, Norman GL, Altorjay I, et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007; 13: 2028-2036. (Pubitemid 46795837)
36. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995; 30: 699-706.
37. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease (IBD). Inflamm Bowel Dis. 2005; 11: 707-712. (Pubitemid 41271173)
38. D'Haens GR, Fedorak R, Lémann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1599-1604.
39. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008; 6: 1218-1224.
40. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 15-22. (Pubitemid 30452574)